The Angeles Clinic and Research Institute, Los Angeles, California.
Cedars-Sinai Medical Center, Los Angeles, California.
Cancer Discov. 2019 Feb;9(2):166-168. doi: 10.1158/2159-8290.CD-18-1447.
Sanchez-Vega and colleagues prospectively demonstrate that both intra- and intertumoral differential expression of the receptor tyrosine kinases HER2, EGFR, and MET dictate sensitivity to the pan-HER inhibitor afatinib in a phase II trial of trastuzumab-refractory -amplified gastroesophageal adenocarcinomas. Rapid autopsy, tissue-based genomic characterization, and molecular imaging provide complementary information and may aid in selecting optimal patients for targeted monotherapy versus combination approaches in gastroesophageal adenocarcinomas..
桑切斯-维加（Sanchez-Vega）及其同事前瞻性地证明，受体酪氨酸激酶 HER2、EGFR 和 MET 的肿瘤内和肿瘤间差异表达决定了曲妥珠单抗耐药扩增胃食管腺癌患者对 pan-HER 抑制剂阿法替尼的敏感性，这是一项 II 期临床试验的结果。快速尸检、基于组织的基因组特征分析和分子成像提供了互补信息，可能有助于在胃食管腺癌中选择最佳的靶向单药治疗或联合治疗的患者。
